BiotechTube
AlzeCure Pharma

AlzeCure Pharma

Stockholm, Sweden· Est.
alzecurepharma.se
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $32.5M

Overview

AlzeCure Pharma is a clinical-stage biotech company developing novel therapies for Alzheimer's disease, cognitive disorders, and neuropathic pain through its three proprietary platforms: NeuroRestore (symptomatic), Alzstatin (disease-modifying), and Painless. Its lead asset, NeuroRestore ACD856, is being prepared for a Phase 2a trial in Alzheimer's with support from a EUR 2.5 million EU grant. The company is publicly listed on Nasdaq First North Premier Growth Market and follows a business model of internal R&D through early clinical phases followed by out-licensing.

Alzheimer's DiseaseCognitive DisordersNeuropathic PainOsteoarthritis Pain

Technology Platform

Three proprietary platforms: 1) NeuroRestore® for symptomatic cognitive treatment via neurotrophin modulation, 2) Alzstatin® for disease-modifying Alzheimer's therapy targeting amyloid/tau, and 3) Painless for neuropathic and severe pain (including ACD440 and TrkA-NAM projects).

Funding History

3
Total raised:$32.5M
IPO$15M
Series B$12M
Series A$5.5M

Opportunities

The Alzheimer's disease market represents a massive unmet need with recent drug approvals validating the space and highlighting demand for better options.
The company's multi-platform approach and the Orphan Drug Designation for ACD440 in erythromelalgia provide additional, niche market opportunities.
Non-dilutive funding, like the EIC grant, supports development while preserving shareholder value.

Risk Factors

High risk of clinical trial failure, particularly in the challenging Alzheimer's disease field.
The company is pre-revenue and dependent on raising additional capital to fund operations.
Intense competition from larger pharmaceutical companies with greater resources in both Alzheimer's and pain therapeutics.

Competitive Landscape

In Alzheimer's, AlzeCure competes with large pharma (e.g., Biogen/Eisai, Lilly) developing disease-modifying antibodies and a wide range of biotechs targeting novel pathways. In neuropathic pain, the competitive landscape includes both generic and novel non-opioid therapies. AlzeCure's differentiation lies in its unique neurotrophin modulation mechanism (NeuroRestore) and its focused platform strategy.

More companies in Sweden →